Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bausch + Lomb, a eye health company, has acquired assets and intellectual property of Miochol-E from affiliates of Novartis.
Subscribe to our email newsletter
Miochol-E is an injectable miotic pharmaceutical used during certain eye surgeries to constrict the pupil.
As per the agreement, Novartis will provide technical assistance to Bausch + Lomb to assist in the transfer of Miochol-E manufacturing.
Bausch + Lomb president of global pharmaceuticals Dan Wechsler said that closure of this acquisition is a terrific gain for Bausch + Lomb pharmaceuticals.
“Miochol-E not only continues to diversify our ophthalmic portfolio, it allows patients to continue to benefit from this well-known product,” Wechsler said.